Article
Novel Therapies in Chronic Lymphocytic Leukemia: A Rapidly Changing Landscape.
Current treatment options in oncology - 13 Mar 2020
Iovino Lorenzo, Shadman Mazyar
Abstract excerpt
OPINION STATEMENT: Treatment landscape of chronic lymphocytic leukemia (CLL) has changed since 2014 after the introduction of inhibitors of B-cell receptor signaling pathway (ibrutinib, acalabrutinib, idelalisib and duvelisib) and the inhibitor of the anti-apoptotic protein BCL-2 (venetoclax). In 2019, novel agents were upgraded from being a "great treatment option" to the "preferred choice" for all lines of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
